Angion Biomedica Corporation

Dong Sung Lim

Bijoy Panicker

Dawoon Jung

Rama K Mishra

Lambertus J W M Oehlen

An-Hu Li

James G Tarrant

Xiaokang Zhu

Satish Kumar Sakilam

Itzhak D Goldberg

David E Smith

Prakash Narayan

Dibyendu Dana

Satishkumar Gadhiya

Quaisar Ali

Swarnalatha Paka

Lambertus Jwm Oehlen

Lambertus JWM Oehlen

The present invention provides compounds having formula (I): and pharmaceutically acceptable salts thereof, wherein Cy1, Cy2, Cy3, R, R, R, R, Aand Aare as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases in which inhibiting ROCK1, ROCK2, or ROCK1/2 has a therapeutically useful role.

Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors

The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving abnormal or excessive fibrosis.

Antifibrotic compounds and uses thereof

The present disclosure provides solid forms of (E)-3-[2-(2-thienyl)vinyl]-1H-pyrazole, compositions thereof, and methods of making and using the same.

Solid forms of (E)-3-[2-(2-thienyl)vinyl]-1H-pyrazole

The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving fibrosis and proliferation, and where anti-fibrotic or anti-proliferative activity is beneficial.

Cytochrome P450 inhibitors and uses thereof

The present invention provides compounds having the general structural formula (I), and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving abnormal or excessive fibrosis. 

The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving fibrosis and proliferation, and where anti-fibrotic or anti-proliferative activity is beneficial. 

Compounds and pharmaceutical compositions are provided that inhibit the activity of poly ADP-ribose synthetase (PARP). Such compounds are useful in the treatment of various diseases, conditions and injuries such as stroke, myocardial infarction, ischemia-perfusion injury in various organs, traumatic brain injury, atherosclerosis, inflammatory diseases and cancer.

Growing community of inventors

Fair Lawn, NJ, United States of America

Dong Sung Lim